Cancer Genetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cherry hill, n.j., dec. 26, 2023 (globe newswire) -- vyant bio, inc. (“vyant bio” or “company”) (otc: vynt) is providing an update to shareholders regarding its winddown activities pursuant to its plan of liquidation and dissolution following the sale of substantially all of its assets. vyant bio's board of directors has filed its certificate of dissolution with the state of delaware with an effective time of 5:00 p.m. on december 29, 2023, after which the company's stock will cease trading on the otc, and the holders of shares of the company's common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, pursuant to and in accordance with the plan of dissolution.

Cherry hill, n.j., nov. 10, 2023 (globe newswire) -- vyant bio, inc. (“vyant bio” or “company”) (otc: vynt) is providing an update to shareholders regarding its winddown activities pursuant to its plan of liquidation and dissolution following the sale of substantially all of its assets. vyant bio's board of directors currently anticipates that it will file a certificate of dissolution with the state of delaware in late december 2023, after which the company's common stock will cease to trade and holders of shares of the company's common stock will cease to have any rights in respect of that stock, except the right of holders at the date we file the certificate of dissolution to receive distributions, if any, pursuant to and in accordance with the plan of dissolution.

Cherry hill, n.j., nov. 01, 2023 (globe newswire) -- vyant bio, inc. (“vyant bio” or “company”) (otc: vynt) is announcing the results of its special meeting of stockholders on november 1, 2023 (the “special meeting”).

Cherry hill, n.j., oct. 24, 2023 (globe newswire) -- vyant bio, inc. (“vyant bio” or “company”) (otc: vynt) announced that it has completed the sale of all or substantially all of the assets of the company (the “sale”) pursuant to an asset purchase agreement dated july 13, 2023.

Cherry hill, n.j., oct. 19, 2023 (globe newswire) -- vyant bio, inc. (“vyant bio” or “company”) (otc: vynt) announced that its special meeting of stockholders on october 19, 2023 (the “special meeting”) was reconvened resulting in the approval of the sale of all or substantially all of the assets of the company.

Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist from the exchange.

Vyant Bio (NASDAQ: VYNT ) stock is taking a beating on Tuesday after the biotechnology company announced plans to delist its shares. According to a press release, the company's Board of Directors determined that a voluntary delisting of shares was in order.

Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agreed in principle to step down from their respective positions, effective today, February 3, to preserve cash for the execution of an orderly wind-down process.  Roberts will remain a member of the board of directors, while chief financial officer Andrew LaFrence will assume the position of president CEO to lead the company through the period of transition, New Jersey-based Vyant said in a statement.

Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. The biotechnology company also said it is participating in BIO's One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.

Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Dr. Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Operator Thank you for standing by.

Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at least the end of 2023. The company had $9.4 million of cash and equivalents as of September 30.

Vyant Bio (NASDAQ:VYNT) Inc senior scientist Matthew Green delivered poster presentations this week at the Loulou Foundation's CDKL5 forum held in Boston.  CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a rare neurodevelopmental condition caused by pathogenic mutations in the CDKL5 gene.

Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, allowing Reaction to expand its suite of drug discovery services. According to Vyant Bio (NASDAQ:VYNT), Reaction will retain US personnel at vivoPharm, located in Hershey, Pennsylvania, which includes in vitro and in vivo capabilities.

- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases

CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference. The event is being held from September 12-14, 2022. Registered attendees can access the recorded presentation on-demand (24x7) for 90 days.